Sarcopenia in Lung Cancer: A Narrative Review

References

• Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997;127(5 Suppl):990S–1S. doi: 10.1093/jn/127.5.990S
   PubMed Web of Science ®Google Scholar
• Morley JE, Abbatecola AM, Argiles JM, Baracos V, Bauer J, Bhasin S, Cederholm T, Coats AJS, Cummings SR, Evans WJ, et al. Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc. 2011;12(6):403–9. doi: 10.1016/j.jamda.2011.04.014
   PubMed Web of Science ®Google Scholar
• Studenski SA, Peters KW, Alley DE, Cawthon PM, McLean RR, Harris TB, Ferrucci L, Guralnik JM, Fragala MS, Kenny AM, et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci. 2014;69(5):547–58. doi: 10.1093/gerona/glu010
   PubMed Web of Science ®Google Scholar
• Chen L-K, Liu L-K, Woo J, Assantachai P, Auyeung T-W, Bahyah KS, Chou M-Y, Chen L-Y, Hsu P-S, Krairit O, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc. 2014;15(2):95–101. doi: 10.1016/j.jamda.2013.11.025
   PubMed Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31. doi: 10.1093/ageing/afy169
   PubMed Web of Science ®Google Scholar
• Bischoff-Ferrari HA, Orav JE, Kanis JA, Rizzoli R, Schlögl M, Staehelin HB, Willett WC, Dawson-Hughes B. Comparative performance of current definitions of sarcopenia against the prospective incidence of falls among community-dwelling seniors age 65 and older. Osteoporos Int. 2015;26(12):2793–802. doi: 10.1007/s00198-015-3194-y
   PubMed Web of Science ®Google Scholar
• Malmstrom TK, Miller DK, Simonsick EM, Ferrucci L, Morley JE. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 2016;7(1):28–36. doi: 10.1002/jcsm.12048
   PubMed Web of Science ®Google Scholar
• Bone AE, Hepgul N, Kon S, Maddocks M. Sarcopenia and frailty in chronic respiratory disease. Chron Respir Dis. 2017;14(1):85–99. doi: 10.1177/1479972316679664
   PubMed Web of Science ®Google Scholar
• De Buyser SL, Petrovic M, Taes YE, Toye KRC, Kaufman J-M, Lapauw B, Goemaere S. Validation of the FNIH sarcopenia criteria and SOF frailty index as predictors of long-term mortality in ambulatory older men. Age Ageing. 2016;45(5):602–8. doi: 10.1093/ageing/afw071
   PubMed Web of Science ®Google Scholar
• Xia L, Zhao R, Wan Q, Wu Y, Zhou Y, Wang Y, Cui Y, Shen X, Wu X. Sarcopenia and adverse health-related outcomes: an umbrella review of meta-analyses of observational studies. Cancer Med. 2020;9(21):7964–78. 10.1002/cam4.3428
   PubMed Web of Science ®Google Scholar
• Prado CMM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, Baracos VE. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9(7):629–35. doi: 10.1016/S1470-2045(08)70153-0
   PubMed Web of Science ®Google Scholar
• Baracos VE, Reiman T, Mourtzakis M, Gioulbasanis I, Antoun S. Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr. 2010;91(4):1133S–7S. doi: 10.3945/ajcn.2010.28608C
   PubMed Web of Science ®Google Scholar
• Fujiwara N, Nakagawa H, Kudo Y, Tateishi R, Taguri M, Watadani T, Nakagomi R, Kondo M, Nakatsuka T, Minami T, et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol. 2015;63(1):131–40. doi: 10.1016/j.jhep.2015.02.031
   PubMed Web of Science ®Google Scholar
• Collins J, Noble S, Chester J, Coles B, Byrne A. The assessment and impact of sarcopenia in lung cancer: a systematic literature review. BMJ Open. 2014;4(1):e003697. doi: 10.1136/bmjopen-2013-003697
   PubMed Web of Science ®Google Scholar
• Buentzel J, Heinz J, Bleckmann A, Bauer C, Röver C, Bohnenberger H, Saha S, Hinterthaner M, Baraki H, Kutschka I, et al. Sarcopenia as prognostic factor in lung cancer patients: a systematic review and meta-analysis. Anticancer Res. 2019;39(9):4603–12. doi: 10.21873/anticanres.13640
   PubMed Web of Science ®Google Scholar
• Deng HY, Zha P, Hou L, Huang KL. Does sarcopenia have any impact on survival of patients with surgically treated non-small-cell lung cancer? Interact Cardiovasc Thorac Surg. 2019;29(1):144–7. doi: 10.1093/icvts/ivz039
   PubMed Web of Science ®Google Scholar
• Deng HY, Hou L, Zha P, Huang KL, Peng L. Sarcopenia is an independent unfavorable prognostic factor of non-small cell lung cancer after surgical resection: a comprehensive systematic review and meta-analysis. Eur J Surg Oncol. 2019;45(5):728–35. doi: 10.1016/j.ejso.2018.09.026
   PubMed Web of Science ®Google Scholar
• Nishimura JM, Ansari AZ, D’Souza DM, Moffatt-Bruce SD, Merritt RE, Kneuertz PJ. Computed tomography-assessed skeletal muscle mass as a predictor of outcomes in lung cancer surgery. Ann Thorac Surg. 2019;108(5):1555–64. doi: 10.1016/j.athoracsur.2019.04.090
   PubMed Web of Science ®Google Scholar
• Yang M, Shen Y, Tan L, Li W. Prognostic value of sarcopenia in lung cancer: a systematic review and meta-analysis. Chest. 2019;156(1):101–11. doi: 10.1016/j.chest.2019.04.115
   PubMed Web of Science ®Google Scholar
• Go S-I, Park MJ, Song H-N, Kang MH, Park HJ, Jeon KN, Kim S-H, Kim MJ, Kang J-H, Lee G-W, et al. Sarcopenia and inflammation are independent predictors of survival in male patients newly diagnosed with small cell lung cancer. Support Care Cancer. 2016;24(5):2075–84. doi: 10.1007/s00520-015-2997-x
   PubMed Web of Science ®Google Scholar
• Kim EY, Lee HY, Kim YS, Park I, Ahn HK, Cho EK, Jeong YM, Kim JH. Prognostic significance of cachexia score assessed by CT in male patients with small cell lung cancer. Eur J Cancer Care. 2018;27(1):e12695. doi: 10.1111/ecc.12695
   Web of Science ®Google Scholar
• Wang J, Cao L, Xu S. Sarcopenia affects clinical efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients: a systematic review and meta-analysis. Int Immunopharmacol. 2020;88:106907. doi: 10.1016/j.intimp.2020.106907
   PubMed Web of Science ®Google Scholar
• Kawaguchi Y, Hanaoka J, Ohshio Y, Okamoto K, Kaku R, Hayashi K, Shiratori T, Akazawa A. Does sarcopenia affect postoperative short- and long-term outcomes in patients with lung cancer? A systematic review and meta-analysis. J Thorac Dis. 2021;13(3):1358–69. doi: 10.21037/jtd-20-3072
   PubMed Web of Science ®Google Scholar
• Ren B, Shen J, Qian Y, Zhou T. Sarcopenia as a determinant of the efficacy of immune checkpoint inhibitors in non-small cell lung cancer: a meta-analysis. Nutr Cancer. 2022; 1–11.
   Web of Science ®Google Scholar
• Lin T-Y, Chen Y-F, Wu W-T, Han D-S, Tsai I-C, Chang K-V, Özçakar L. Impact of sarcopenia on the prognosis and treatment of lung cancer: an umbrella review. Discov Oncol. 2022;13(1):115. doi: 10.1007/s12672-022-00576-0
   PubMedGoogle Scholar
• Deng HY, Zha P, Peng L, Hou L, Huang KL, Li XY. Preoperative sarcopenia is a predictor of poor prognosis of esophageal cancer after esophagectomy: a comprehensive systematic review and meta-analysis. Dis Esophagus. 2019;32(3)
   Web of Science ®Google Scholar
• Nagurney JT, Brown DF, Sane S, Weiner JB, Wang AC, Chang Y. The accuracy and completeness of data collected by prospective and retrospective methods. Acad Emerg Med. 2005;12(9):884–95. doi: 10.1197/j.aem.2005.04.021
   PubMed Web of Science ®Google Scholar
• Kim EY, Lee HY, Kim KW, Lee J-I, Kim YS, Choi W-J, Kim JH. Preoperative computed tomography-determined sarcopenia and postoperative outcome after surgery for non-small cell lung cancer. Scand J Surg. 2018;107(3):244–51. doi: 10.1177/1457496917748221
   PubMed Web of Science ®Google Scholar
• Madariaga MLL, Troschel FM, Best TD, Knoll SJ, Gaissert HA, Fintelmann FJ. Low thoracic skeletal muscle area predicts morbidity after pneumonectomy for lung cancer. Ann Thorac Surg. 2020;109(3):907–13. doi: 10.1016/j.athoracsur.2019.10.041
   PubMed Web of Science ®Google Scholar
• Fintelmann FJ, Troschel FM, Mario J, Chretien YR, Knoll SJ, Muniappan A, Gaissert HA. Thoracic skeletal muscle is associated with adverse outcomes after lobectomy for lung cancer. Ann Thorac Surg. 2018;105(5):1507–15. doi: 10.1016/j.athoracsur.2018.01.013
   PubMed Web of Science ®Google Scholar
• Miller JA, Harris K, Roche C, Dhillon S, Battoo A, Demmy T, Nwogu CE, Dexter EU, Hennon M, Picone A, et al. Sarcopenia is a predictor of outcomes after lobectomy. J Thorac Dis. 2018;10(1):432–40. doi: 10.21037/jtd.2017.12.39
   PubMed Web of Science ®Google Scholar
• Srdic D, Plestina S, Sverko-Peternac A, Nikolac N, Simundic AM, Samarzija M. Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value. Support Care Cancer. 2016;24(11):4495–502. doi: 10.1007/s00520-016-3287-y
   PubMed Web of Science ®Google Scholar
• Sjøblom B, Grønberg BH, Benth JŠ, Baracos VE, Fløtten Ø, Hjermstad MJ, Aass N, Jordhøy M. Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer. Lung Cancer. 2015;90(1):85–91. doi: 10.1016/j.lungcan.2015.07.001
   PubMed Web of Science ®Google Scholar
• Pataer A, Weissferdt A, Correa AM, Vaporciyan AA, Sepesi B, Heymach JV, Berezowska S, Cascone T, Swisher SG. Major pathologic response and prognostic score predict survival in patients with lung cancer receiving neoadjuvant chemotherapy. JTO Clin Res Rep. 2022;3(11):100420. doi: 10.1016/j.jtocrr.2022.100420
   PubMedGoogle Scholar
• Kimura M, Naito T, Kenmotsu H, Taira T, Wakuda K, Oyakawa T, Hisamatsu Y, Tokito T, Imai H, Akamatsu H, et al. Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer. Support Care Cancer. 2015;23(6):1699–708. doi: 10.1007/s00520-014-2534-3
   PubMed Web of Science ®Google Scholar
• Jafri SH, Previgliano C, Khandelwal K, Shi R. Cachexia Index in Advanced Non-Small-Cell Lung Cancer Patients. Clin Med Insights Oncol. 2015;9:87–93. doi: 10.4137/CMO.S30891
   PubMed Web of Science ®Google Scholar
• Stene GB, Helbostad JL, Amundsen T, Sørhaug S, Hjelde H, Kaasa S, Grønberg BH. Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer. Acta Oncol. 2015;54(3):340–8. doi: 10.3109/0284186X.2014.953259
   PubMed Web of Science ®Google Scholar
• Sjøblom B, Grønberg BH, Wentzel-Larsen T, Baracos VE, Hjermstad MJ, Aass N, Bremnes RM, Fløtten Ø, Bye A, Jordhøy M, et al. Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer. Clin Nutr. 2016;35(6):1386–93. doi: 10.1016/j.clnu.2016.03.010
   PubMed Web of Science ®Google Scholar
• Kim EY, Kim YS, Park I, Ahn HK, Cho EK, Jeong YM. Prognostic significance of CT-determined sarcopenia in patients with small-cell lung cancer. J Thorac Oncol. 2015;10(12):1795–9. doi: 10.1097/JTO.0000000000000690
   PubMed Web of Science ®Google Scholar
• Bowden JCS, Williams LJ, Simms A, Price A, Campbell S, Fallon MT, Fearon KCH. Prediction of 90 day and overall survival after chemoradiotherapy for lung cancer: role of performance status and body composition. Clin Oncol (R Coll Radiol). 2017;29(9):576–84. doi: 10.1016/j.clon.2017.06.005
   PubMed Web of Science ®Google Scholar
• Mitsuyoshi T, Matsuo Y, Itou H, Shintani T, Iizuka Y, Kim YH, Mizowaki T. Evaluation of a prognostic scoring system based on the systemic inflammatory and nutritional status of patients with locally advanced non-small-cell lung cancer treated with chemoradiotherapy. J Radiat Res. 2018;59(1):50–7. doi: 10.1093/jrr/rrx060
   PubMed Web of Science ®Google Scholar
• Kiss N, Beraldo J, Everitt S. Early skeletal muscle loss in non-small cell lung cancer patients receiving chemoradiation and relationship to survival. Support Care Cancer. 2019;27(7):2657–64. doi: 10.1007/s00520-018-4563-9
   PubMed Web of Science ®Google Scholar
• Degens JHRJ, Sanders KJC, de Jong EEC, Groen HJM, Smit EF, Aerts JG, Schols AMWJ, Dingemans A-MC. The prognostic value of early onset, CT derived loss of muscle and adipose tissue during chemotherapy in metastatic non-small cell lung cancer. Lung Cancer. 2019;133:130–5. doi: 10.1016/j.lungcan.2019.05.021
   PubMed Web of Science ®Google Scholar
• Abbass T, Dolan RD, MacLeod N, Horgan PG, Laird BJ, McMillan DC. Comparison of the prognostic value of MUST, ECOG-PS, mGPS and CT derived body composition analysis in patients with advanced lung cancer. Clin Nutr ESPEN. 2020;40:349–56. doi: 10.1016/j.clnesp.2020.08.003
   PubMed Web of Science ®Google Scholar
• Dolan RD, Maclay JD, Abbass T, Colville D, Buali F, MacLeod N, McSorley ST, Horgan PG, McMillan DC. The relationship between (18)F-FDG-PETCT-derived tumour metabolic activity, nutritional risk, body composition, systemic inflammation and survival in patients with lung cancer. Sci Rep. 2020;10(1):20819. doi: 10.1038/s41598-020-77269-7
   PubMed Web of Science ®Google Scholar
• Minami S, Ihara S, Komuta K. Sarcopenia and visceral adiposity are not independent prognostic markers for extensive disease of small-cell lung cancer: A Single-Centered Retrospective Cohort Study. World J Oncol. 2020;11(4):139–49. doi: 10.14740/wjon1289
   PubMedGoogle Scholar
• Katsui K, Ogata T, Sugiyama S, Yoshio K, Kuroda M, Hiraki T, Kiura K, Maeda Y, Toyooka S, Kanazawa S, et al. Sarcopenia is associated with poor prognosis after chemoradiotherapy in patients with stage III non-small-cell lung cancer: a retrospective analysis. Sci Rep. 2021;11(1):11882. doi: 10.1038/s41598-021-91449-z
   PubMed Web of Science ®Google Scholar
• Lee J, Kim EY, Kim E, Kim KG, Kim YJ, Kim YS, Ahn HK, Lee S-W. Longitudinal changes in skeletal muscle mass in patients with advanced squamous cell lung cancer. Thorac Cancer. 2021;12(11):1662–7. doi: 10.1111/1759-7714.13958
   PubMed Web of Science ®Google Scholar
• Wang K, Long W, Sima X, Zhao Y, Xiao B, Gulizeba H, Huang Y. Sarcopenia defined by skeletal muscle mass index at the third lumbar vertebra is a prognostic factor for extensive-stage small cell lung cancer patients: a retrospective study. J Thorac Dis. 2022;14(7):2645–51. doi: 10.21037/jtd-22-782
   PubMed Web of Science ®Google Scholar
• Miyamoto Y, Baba Y, Sakamoto Y, Ohuchi M, Tokunaga R, Kurashige J, Hiyoshi Y, Iwagami S, Yoshida N, Yoshida M, et al. Sarcopenia is a negative prognostic factor after curative resection of colorectal cancer. Ann Surg Oncol. 2015;22(8):2663–8. doi: 10.1245/s10434-014-4281-6
   PubMed Web of Science ®Google Scholar
• Miyamoto Y, Baba Y, Sakamoto Y, Ohuchi M, Tokunaga R, Kurashige J, Hiyoshi Y, Iwagami S, Yoshida N, Watanabe M, et al. Negative impact of skeletal muscle loss after systemic chemotherapy in patients with unresectable colorectal cancer. PLoS One. 2015;10(6):e0129742. doi: 10.1371/journal.pone.0129742
   PubMed Web of Science ®Google Scholar
• Rollins KE, Tewari N, Ackner A, Awwad A, Madhusudan S, Macdonald IA, Fearon KCH, Lobo DN. The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma. Clin Nutr. 2016;35(5):1103–9. doi: 10.1016/j.clnu.2015.08.005
   PubMed Web of Science ®Google Scholar
• Antoun S, Lanoy E, Iacovelli R, Albiges-Sauvin L, Loriot Y, Merad-Taoufik M, Fizazi K, di Palma M, Baracos VE, Escudier B, et al. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer. 2013;119(18):3377–84. doi: 10.1002/cncr.28218
   PubMed Web of Science ®Google Scholar
• Acharyya S, Ladner KJ, Nelsen LL, Damrauer J, Reiser PJ, Swoap S, Guttridge DC. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest. 2004;114(3):370–8. doi: 10.1172/JCI200420174
   PubMed Web of Science ®Google Scholar
• Barker T, Fulde G, Moulton B, Nadauld LD, Rhodes T. An elevated neutrophil-to-lymphocyte ratio associates with weight loss and cachexia in cancer. Sci Rep. 2020;10(1):7535. doi: 10.1038/s41598-020-64282-z
   PubMed Web of Science ®Google Scholar
• Neagu M, Constantin C, Popescu ID, Zipeto D, Tzanakakis G, Nikitovic D, Fenga C, Stratakis CA, Spandidos DA, Tsatsakis AM, et al. Inflammation and Metabolism in Cancer Cell-Mitochondria Key Player. Front Oncol. 2019;9:348. doi: 10.3389/fonc.2019.00348
   PubMed Web of Science ®Google Scholar
• Bardoscia L, Besutti G, Pellegrini M, Pagano M, Bonelli C, Bonelli E, Braglia L, Cozzi S, Roncali M, Iotti C, et al. Impact of low skeletal muscle mass and quality on clinical outcomes in patients with head and neck cancer undergoing (chemo)radiation. Front Nutr. 2022;9:994499. doi: 10.3389/fnut.2022.994499
   PubMed Web of Science ®Google Scholar
• Aleixo GFP, Shachar SS, Nyrop KA, Muss HB, Malpica L, Williams GR. Myosteatosis and prognosis in cancer: systematic review and meta-analysis. Crit Rev Oncol Hematol. 2020;145:102839. doi: 10.1016/j.critrevonc.2019.102839
   PubMed Web of Science ®Google Scholar
• Prado CMM, Lima ISF, Baracos VE, Bies RR, McCargar LJ, Reiman T, Mackey JR, Kuzma M, Damaraju VL, Sawyer MB, et al. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol. 2011;67(1):93–101. doi: 10.1007/s00280-010-1288-y
   PubMed Web of Science ®Google Scholar
• Prado CMM, Baracos VE, Xiao J, Birdsell L, Stuyckens K, Park YC, Parekh T, Sawyer MB. The association between body composition and toxicities from the combination of Doxil and trabectedin in patients with advanced relapsed ovarian cancer. Appl Physiol Nutr Metab. 2014;39(6):693–8. doi: 10.1139/apnm-2013-0403
   PubMed Web of Science ®Google Scholar
• Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33(5):997–1006. doi: 10.1139/H08-075
   PubMed Web of Science ®Google Scholar
• Kikuchi R, Takoi H, Ishiwari M, Toriyama K, Kono Y, Togashi Y, Abe S. Impact of sarcopenia on chemotherapy-triggered exacerbation of interstitial lung disease in patients with non-small cell lung cancer. Thorac Cancer. 2022;13(4):549–56. doi: 10.1111/1759-7714.14294
   PubMed Web of Science ®Google Scholar
• Halvorsen TO, Valan CD, Slaaen M, Gronberg BH. Associations between muscle measures, survival, and toxicity in patients with limited stage small cell lung cancer. J Cachexia Sarcopenia Muscle. 2020;11(5):1283–90. doi: 10.1002/jcsm.12583
   PubMed Web of Science ®Google Scholar
• Cortellini A, Verna L, Porzio G, Bozzetti F, Palumbo P, Masciocchi C, Cannita K, Parisi A, Brocco D, Tinari N, et al. Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A “hypothesis-generator” preliminary report. Thorac Cancer. 2019;10(2):347–51. doi: 10.1111/1759-7714.12965
   PubMed Web of Science ®Google Scholar
• Sjøblom B, Benth JŠ, Grønberg BH, Baracos VE, Sawyer MB, Fløtten Ø, Hjermstad MJ, Aass N, Jordhøy M. Drug dose per kilogram lean body mass predicts hematologic toxicity from carboplatin-doublet chemotherapy in advanced non-small-cell lung cancer. Clin Lung Cancer. 2017;18(2):e129–e36. doi: 10.1016/j.cllc.2016.09.008
   PubMed Web of Science ®Google Scholar
• de Jong C, Chargi N, Herder GJM, van Haarlem SWA, van der Meer F, van Lindert ASR, Ten Heuvel A, Brouwer J, de Jong PA, Devriese LA, et al. The association between skeletal muscle measures and chemotherapy-induced toxicity in non-small cell lung cancer patients. J Cachexia Sarcopenia Muscle. 2022;13(3):1554–64. doi: 10.1002/jcsm.12967
   PubMed Web of Science ®Google Scholar
• Tsukagoshi M, Yokobori T, Yajima T, Maeno T, Shimizu K, Mogi A, Araki K, Harimoto N, Shirabe K, Kaira K, et al. Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer. Medicine (Baltimore). 2020;99(7):e19059. doi: 10.1097/MD.0000000000019059
   PubMed Web of Science ®Google Scholar
• Bolte FJ, McTavish S, Wakefield N, Shantzer L, Hubbard C, Krishnaraj A, Novicoff W, Gentzler RD, Hall RD. Association of sarcopenia with survival in advanced NSCLC patients receiving concurrent immunotherapy and chemotherapy. Front Oncol. 2022;12:986236. doi: 10.3389/fonc.2022.986236
   PubMed Web of Science ®Google Scholar
• Li S, Liu Z, Ren Y, Liu J, Lv S, He P, Yang Y, Sun Y, Chang J, Luo D, et al. Sarcopenia was a poor prognostic predictor for patients with advanced lung cancer treated with immune checkpoint inhibitors. Front Nutr. 2022;9:900823. doi: 10.3389/fnut.2022.900823
   PubMed Web of Science ®Google Scholar
• Nie X, Zhang P, Gao JY, Cheng G, Liu W, Li L. Sarcopenia as a predictor of initial administration dose of afatinib in patients with advanced non-small cell lung cancer. Thorac Cancer. 2021;12(12):1824–30. doi: 10.1111/1759-7714.13934
   PubMed Web of Science ®Google Scholar
• Rossi S, Di Noia V, Tonetti L, Strippoli A, Basso M, Schinzari G, Cassano A, Leone A, Barone C, D’Argento E, et al. Does sarcopenia affect outcome in patients with non-small-cell lung cancer harboring EGFR mutations? Future Oncol. 2018;14(10):919–26. doi: 10.2217/fon-2017-0499
   PubMed Web of Science ®Google Scholar
• Topcu A, Ozturk A, Yurtsever I, Besiroglu M, Yasin AI, Turk HM, Seker M. The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma. Bosn J Basic Med Sci. 2022;22(6):982–91. doi: 10.17305/bjbms.2022.7147
   PubMed Web of Science ®Google Scholar
• Arrieta O, De la Torre-Vallejo M, López-Macías D, Orta D, Turcott J, Macedo-Pérez E-O, Sánchez-Lara K, Ramírez-Tirado L-A, Baracos VE. Nutritional status, body surface, and low lean body mass/body mass index are related to dose reduction and severe gastrointestinal toxicity induced by afatinib in patients with non-small cell lung cancer. Oncologist. 2015;20(8):967–74. doi: 10.1634/theoncologist.2015-0058
   PubMed Web of Science ®Google Scholar
• Yi X, Chen Q, Yang J, Jiang D, Zhu L, Liu H, Pang P, Zeng F, Chen C, Gong G, et al. CT-based sarcopenic nomogram for predicting progressive disease in advanced non-small-cell lung cancer. Front Oncol. 2021;11:643941. doi: 10.3389/fonc.2021.643941
   PubMed Web of Science ®Google Scholar
• Minami S, Ihara S, Tanaka T, Komuta K. Sarcopenia and visceral adiposity did not affect efficacy of immune-checkpoint inhibitor monotherapy for pretreated patients with advanced non-small cell lung cancer. World J Oncol. 2020;11(1):9–22. doi: 10.14740/wjon1225
   PubMedGoogle Scholar
• Nishioka N, Naito T, Notsu A, Mori K, Kodama H, Miyawaki E, Miyawaki T, Mamesaya N, Kobayashi H, Omori S, et al. Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non-small cell lung cancer. Cancer Med. 2021;10(1):247–56. doi: 10.1002/cam4.3631
   PubMed Web of Science ®Google Scholar
• Nishioka N, Uchino J, Hirai S, Katayama Y, Yoshimura A, Okura N, et al. Association of sarcopenia with and efficacy of anti-PD-1/PD-L1 therapy in non-small-cell lung cancer. J Clin Med. 2019;8(4)
   Web of Science ®Google Scholar
• Rounis K, Makrakis D, Tsigkas A-P, Georgiou A, Galanakis N, Papadaki C, Monastirioti A, Vamvakas L, Kalbakis K, Vardakis N, et al. Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study. Transl Lung Cancer Res. 2021;10(8):3538–49. doi: 10.21037/tlcr-21-460
   PubMed Web of Science ®Google Scholar
• Shiroyama T, Nagatomo I, Koyama S, Hirata H, Nishida S, Miyake K, Fukushima K, Shirai Y, Mitsui Y, Takata S, et al. Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study. Sci Rep. 2019;9(1):2447. doi: 10.1038/s41598-019-39120-6
   PubMed Web of Science ®Google Scholar
• Takada K, Yoneshima Y, Tanaka K, Okamoto I, Shimokawa M, Wakasu S, Takamori S, Toyokawa G, Oba T, Osoegawa A, et al. Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors. J Cancer Res Clin Oncol. 2020;146(5):1217–25. doi: 10.1007/s00432-020-03146-5
   PubMed Web of Science ®Google Scholar
• Tenuta M, Gelibter A, Pandozzi C, Sirgiovanni G, Campolo F, Venneri MA, Caponnetto S, Cortesi E, Marchetti P, Isidori AM, et al. Impact of Sarcopenia and Inflammation on Patients with Advanced Non-Small Cell Lung Cancer (NCSCL) Treated with Immune Checkpoint Inhibitors (ICIs): A Prospective Study. Cancers (Basel). 2021;13(24):6355. doi: 10.3390/cancers13246355
   PubMed Web of Science ®Google Scholar
• Pratesi A, Tarantini F, Bari D. M. Skeletal muscle: an endocrine organ. Clin Cases Miner Bone Metab. 2013;10(1):11–4.
   PubMedGoogle Scholar
• Cinkir HK, Aktas G, Elboga U. Sarcopenia is a predictive marker for response to erlotinib in patients with lung adenocancer. Clin Cancer Investig J. 2021;10(6):294–9.
   Web of Science ®Google Scholar
• Agteresch HJ, Rietveld T, Kerkhofs LG, van den Berg JW, Wilson JH, Dagnelie PC. Beneficial effects of adenosine triphosphate on nutritional status in advanced lung cancer patients: a randomized clinical trial. J Clin Oncol. 2002;20(2):371–8. doi: 10.1200/JCO.2002.20.2.371
   PubMed Web of Science ®Google Scholar
• Beijer S, Hupperets PS, van den Borne BEEM, Wijckmans NEG, Spreeuwenberg C, van den Brandt PA, Dagnelie PC. Randomized clinical trial on the effects of adenosine 5’-triphosphate infusions on quality of life, functional status, and fatigue in preterminal cancer patients. J Pain Symptom Manage. 2010;40(4):520–30. doi: 10.1016/j.jpainsymman.2010.01.023
   PubMed Web of Science ®Google Scholar
• Ulutin HC, Arpaci F, Pak Y. Megestrol acetate for cachexia and anorexia in advanced non-small cell lung cancer: a randomized study comparing two different doses. Tumori. 2002;88(4):277–80. 10.1177/030089160208800406
   PubMed Web of Science ®Google Scholar
• Ruiz-Garcia V, Lopez-Briz E, Carbonell-Sanchis R, Bort-Marti S, Gonzalvez-Perales JL. Megestrol acetate for cachexia-anorexia syndrome. A systematic review. J Cachexia Sarcopenia Muscle. 2018;9(3):444–52. doi: 10.1002/jcsm.12292
   PubMed Web of Science ®Google Scholar
• Awan S, Crosby V, Potter V, Hennig I, Baldwin D, Ndlovu M, Paradine S, Wilcock A. Is clarithromycin a potential treatment for cachexia in people with lung cancer? A Feasibility Study. Lung Cancer. 2017;104:75–8. doi: 10.1016/j.lungcan.2016.12.010
   PubMed Web of Science ®Google Scholar
• Crawford J, Prado CMM, Johnston MA, Gralla RJ, Taylor RP, Hancock ML, Dalton JT. Study design and rationale for the phase 3 clinical development program of enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients (POWER Trials). Curr Oncol Rep. 2016;18(6):37. doi: 10.1007/s11912-016-0522-0
   PubMed Web of Science ®Google Scholar
• Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, Fearon KC. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016;17(4):519–31. doi: 10.1016/S1470-2045(15)00558-6
   PubMed Web of Science ®Google Scholar
• Takayama K, Katakami N, Yokoyama T, Atagi S, Yoshimori K, Kagamu H, Saito H, Takiguchi Y, Aoe K, Koyama A, et al. Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial. Support Care Cancer. 2016;24(8):3495–505. doi: 10.1007/s00520-016-3144-z
   PubMed Web of Science ®Google Scholar
• Fearon KCH, Barber MD, Moses AG, Ahmedzai SH, Taylor GS, Tisdale MJ, Murray GD. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol. 2006;24(21):3401–7. doi: 10.1200/JCO.2005.04.5724
   PubMed Web of Science ®Google Scholar
• Murphy RA, Mourtzakis M, Chu QS, Baracos VE, Reiman T, Mazurak VC. Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer. 2011;117(8):1775–82. doi: 10.1002/cncr.25709
   PubMed Web of Science ®Google Scholar
• Sánchez-Lara K, Turcott JG, Juárez-Hernández E, Nuñez-Valencia C, Villanueva G, Guevara P, De la Torre-Vallejo M, Mohar A, Arrieta O. Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: randomised trial. Clin Nutr. 2014;33(6):1017–23. doi: 10.1016/j.clnu.2014.03.006
   PubMed Web of Science ®Google Scholar
• Turcott JG, Del Rocío Guillen Núñez M, Flores-Estrada D, Oñate-Ocaña LF, Zatarain-Barrón ZL, Barrón F, Arrieta O. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer. 2018;26(9):3029–38. doi: 10.1007/s00520-018-4154-9
   PubMed Web of Science ®Google Scholar
• Stewart Coats AJ, Ho GF, Prabhash K, von Haehling S, Tilson J, Brown R, Beadle J, Anker SD, for and on behalf of the ACT‐ONE study group Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial). J Cachexia Sarcopenia Muscle. 2016;7(3):355–65. doi: 10.1002/jcsm.12126
   PubMed Web of Science ®Google Scholar
• Rogers ES, MacLeod RD, Stewart J, Bird SP, Keogh JW. A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), resistance training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients–ACCeRT study. BMC Cancer. 2011;11:493. doi: 10.1186/1471-2407-11-493
   PubMed Web of Science ®Google Scholar
• Tobberup R, Carus A, Rasmussen HH, Falkmer UG, Jorgensen MG, Schmidt EB, Jensen NA, Mark EB, Delekta AM, Antoniussen CS, et al. Feasibility of a multimodal intervention on malnutrition in patients with lung cancer during primary anti-neoplastic treatment. Clin Nutr. 2021;40(2):525–33. doi: 10.1016/j.clnu.2020.05.050
   PubMed Web of Science ®Google Scholar
• Maeng CH, Kim B-H, Chon J, Kang WS, Kang K, Woo M, Hong IK, Lee J, Lee KY. Effect of multimodal intervention care on cachexia in patients with advanced cancer compared to conventional management (MIRACLE): an open-label, parallel, randomized, phase 2 trial. Trials. 2022;23(1):281. doi: 10.1186/s13063-022-06221-z
   PubMed Web of Science ®Google Scholar